BACKGROUND: Injection of drugs into the vitreous can lead to intraocular inflammation through infectious and non-infectious processes. Failure to recognize an eye with anterior chamber and vitreous cell as sterile inflammation can lead to unnecessary treatment for endophthalmitis. METHODS: Four cases of uveitis following intravitreal bevacizumab (Avastin) for exudative age-related macular degeneration are described followed by review of the literature. RESULTS: Four patients presented with uveitis. Two patients presented with pain and red eye associated with iritis and two patients with vitritis, several days following intravitreal injection of bevacizumab. No paracentesis was performed and no corneal epithelial defect was created. Both patients with iritis were presumed to have sterile intraocular inflammation since the anterior chamber cell was much greater than the vitreous cell and resolved with cycloplegic and topical corticosteroid therapy. The third patient presented only with vitreous cell which resolved without therapy. The fourth patient had anterior chamber cell and vitreous cell with clumps, which resolved with topical prednisolone acetate. The inflammation resolved in all cases within 1 to 2 weeks. CONCLUSION: There are few published cases of uveitis following bevacizumab. With its rising use, it is important to be aware of its potential to be associated with intraocular inflammation.
BACKGROUND: Injection of drugs into the vitreous can lead to intraocular inflammation through infectious and non-infectious processes. Failure to recognize an eye with anterior chamber and vitreous cell as sterile inflammation can lead to unnecessary treatment for endophthalmitis. METHODS: Four cases of uveitis following intravitreal bevacizumab (Avastin) for exudative age-related macular degeneration are described followed by review of the literature. RESULTS: Four patients presented with uveitis. Two patients presented with pain and red eye associated with iritis and two patients with vitritis, several days following intravitreal injection of bevacizumab. No paracentesis was performed and no corneal epithelial defect was created. Both patients with iritis were presumed to have sterile intraocular inflammation since the anterior chamber cell was much greater than the vitreous cell and resolved with cycloplegic and topical corticosteroid therapy. The third patient presented only with vitreous cell which resolved without therapy. The fourth patient had anterior chamber cell and vitreous cell with clumps, which resolved with topical prednisolone acetate. The inflammation resolved in all cases within 1 to 2 weeks. CONCLUSION: There are few published cases of uveitis following bevacizumab. With its rising use, it is important to be aware of its potential to be associated with intraocular inflammation.
Authors: Christopher Kiss; Stephan Michels; Franz Prager; Günther Weigert; Wolfgang Geitzenauer; Ursula Schmidt-Erfurth Journal: Retina Date: 2006-10 Impact factor: 4.256
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Philip J Rosenfeld; Steven D Schwartz; Mark S Blumenkranz; Joan W Miller; Julia A Haller; James D Reimann; William L Greene; Naveed Shams Journal: Ophthalmology Date: 2005-06 Impact factor: 12.079
Authors: Richard F Spaide; Ketan Laud; Howard F Fine; James M Klancnik; Catherine B Meyerle; Lawrence A Yannuzzi; John Sorenson; Jason Slakter; Yale L Fisher; Michael J Cooney Journal: Retina Date: 2006-04 Impact factor: 4.256
Authors: Darius M Moshfeghi; Peter K Kaiser; Ingrid U Scott; Jonathan E Sears; Matthew Benz; Juan P Sinesterra; Richard S Kaiser; Sophie J Bakri; Raj K Maturi; Jonathan Belmont; Paul M Beer; Timothy G Murray; Hugo Quiroz-Mercado; William F Mieler Journal: Am J Ophthalmol Date: 2003-11 Impact factor: 5.258
Authors: Jost B Jonas; Ulrich H Spandau; Florian Rensch; Stefan Von Baltz; Frank Schlichtenbrede Journal: J Ocul Pharmacol Ther Date: 2007-06 Impact factor: 2.671
Authors: Mehryar Taban; Rishi P Singh; Jeffrey Yau-Huei Chung; Careen Y Lowder; Victor L Perez; Peter K Kaiser Journal: Am J Ophthalmol Date: 2007-07 Impact factor: 5.258
Authors: Timothy W Olsen; Xiao Feng; Kathy Wabner; Karl Csaky; Stefan Pambuccian; J Douglas Cameron Journal: Invest Ophthalmol Vis Sci Date: 2011-07-01 Impact factor: 4.799
Authors: Lu Liu; David A Ammar; Lindsey A Ross; Naresh Mandava; Malik Y Kahook; John F Carpenter Journal: Invest Ophthalmol Vis Sci Date: 2011-02-22 Impact factor: 4.799
Authors: Samuel S Widodo; Ryan A Hutchinson; Yitong Fang; Stefano Mangiola; Paul J Neeson; Phillip K Darcy; Alexander D Barrow; Christopher M Hovens; Marija Dinevska; Stanley S Stylli; Theo Mantamadiotis Journal: Cancer Immunol Immunother Date: 2021-01-03 Impact factor: 6.968
Authors: Rebecca E H Whiting; Jacqueline W Pearce; Daniella P Vansteenkiste; Katherine Bibi; Stefanie Lim; Grace Robinson Kick; Leilani J Castaner; John Sinclair; Sundeep Chandra; Annalisa Nguyen; Charles A O'Neill; Martin L Katz Journal: Exp Eye Res Date: 2020-07-01 Impact factor: 3.467